Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | DVL1 | O14640 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | HNF4A | P41235 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10489814 | 0.83 | LTC4S (0.59) | LTC4SKDM4EPKMDVL1HNF4A | |
| SCHEMBL7381558 | 0.82 | CTSV (0.52) | KDM4EPKMDVL1ALDH1A1 | |
| SCHEMBL7396740 | 0.81 | MGLL (0.52) | ALDH1A1RXFP1PTPN1 | |
| SCHEMBL25430887 | 0.80 | PTPN1 (0.61) | KDM4EHNF4ACYP17A1RXFP1PTPN1 | |
| SCHEMBL1767849 | 0.79 | KMT2A (0.52) | KDM4EALDH1A1RXFP1CA12CA1 | |
| SCHEMBL10249437 | 0.79 | CYP17A1 (0.68) | PPARAPPARGCYP17A1CA12CA1 | |
| SCHEMBL31619048 | 0.79 | KMT2A (0.52) | KDM4EALDH1A1RXFP1CA12CA1 | |
| SCHEMBL27852761 | 0.79 | MEN1 (0.56) | PPARAPPARGALDH1A1CA12CA1 | |
| SCHEMBL222446 | 0.79 | RXFP1 (0.55) | KDM4EPKMRXFP1CA12 | |
| SCHEMBL29702265 | 0.79 | RXFP1 (0.55) | KDM4EPKMRXFP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-102482221-B | bicyclic and tricyclic compounds as KATII inhibitors | PFIZER INC. (US) | 2014-10-22 | — | — | CN | disclosed |
| CN-102482221-A | Bicyclic and tricyclic compounds as KATII inhibitors | PFIZER | 2012-05-30 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | LTC4S 4114/4885KDM4E 1109/4885PKM 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.